<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104050</url>
  </required_header>
  <id_info>
    <org_study_id>OLT1177-03</org_study_id>
    <nct_id>NCT02104050</nct_id>
  </id_info>
  <brief_title>Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain</brief_title>
  <official_title>A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olatec Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olatec Therapeutics LLC</source>
  <brief_summary>
    <textblock>
      The objectives of this trial are to investigate the efficacy and safety of six weeks of&#xD;
      treatment with OLT1177 Gel in subjects with moderate to severe pain associated with&#xD;
      osteoarthritis of the knee following cessation of pain therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on Movement</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Current Knee Pain</measure>
    <time_frame>Baseline (pre-dose) to Baseline (50-min post-dose)</time_frame>
    <description>After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Subscale</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function Subscale</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Rating of Disease</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>Subjects will complete the assessment on a 100-mm Visual Analog Scale (with anchors 0=very good; 100=very poor) in response to the question, 'Considering all the ways osteoarthritis affects you, how well are you doing?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current Knee Pain</measure>
    <time_frame>Baseline to Hours 2-6</time_frame>
    <description>After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness Subscale</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on Movement (VAS, in-clinic)</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on Movement (11-point NRS, diary)</measure>
    <time_frame>Baseline through Week 6</time_frame>
    <description>All evaluations will be on the 11-point Numerical Rating Scale (with anchors 0=no pain; 100=extreme pain) and in response to the following instructions: Please put an &quot;X&quot; over the one number below that best describes your average study knee pain while moving during your daily activities since you woke up this morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication</measure>
    <time_frame>Baseline through Week 6</time_frame>
    <description>Subjects will record the amount, time/date and dose of Rescue Medication use throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 12v2 Health Survey</measure>
    <time_frame>Baseline to Weeks 2, 4 and 6</time_frame>
    <description>The SF-12v2 Health Survey is a multipurpose short-form (SF) general health survey comprised of 12 questions to measure functional health and well-being from the subject's perspective.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical Examination: Number of subjects with clinically significant changes in Physical Examination in major body systems (HEENT, Neck, Cardiovascular, Abdominal, Respiratory, Musculoskeletal, Extremities Skin or Other)</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs: Change from Baseline in Heart Rate (beats per minute)</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs: Change from Baseline in Supine Diastolic Blood Pressure [mmHg]</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs: Change from Baseline in Supine Systolic Blood Pressure [mmHg]</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs: Change from Baseline in Body Temperature (axillary) [°C]</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs: Change from Baseline in respiration rate (respirations per minute)</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Screening through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>Screening through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Subjects experiencing Adverse Events</measure>
    <time_frame>Screening through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Subjects experiencing Serious Adverse Events</measure>
    <time_frame>Screening through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Subjects experiencing Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety Labs: Hematology</measure>
    <time_frame>Baseline through Week 8</time_frame>
    <description>Blood will be drawn for hematology laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Labs: Chemistry</measure>
    <time_frame>Baseline through Week 8</time_frame>
    <description>Blood will be drawn for chemistry laboratory analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 mL of Placebo Gel administered TID for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLT1177 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mL of OLT1177 Gel (5%) administered TID for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel</intervention_name>
    <description>6 mL of Placebo Gel administered TID for 6 weeks</description>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLT1177 Gel</intervention_name>
    <description>6 mL of OLT1177 Gel (5%) administered TID for 6 weeks</description>
    <arm_group_label>OLT1177 Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 45 to 80 years old, inclusive&#xD;
&#xD;
          -  Clinical diagnosis of osteoarthritis in one target knee based on the following&#xD;
             American College of Rheumatology (ACR) criteria:&#xD;
&#xD;
               1. Knee Pain&#xD;
&#xD;
               2. At least 1 of 3:&#xD;
&#xD;
                    -  Age &gt; 50 years&#xD;
&#xD;
                    -  Morning stiffness lasting &lt; 30 minutes&#xD;
&#xD;
                    -  Crepitus on motion&#xD;
&#xD;
               3. Osteophytes on radiograph&#xD;
&#xD;
          -  Symptoms associated with osteoarthritis of the knee (including pain) for ≥ 6 months&#xD;
             prior to Screening&#xD;
&#xD;
          -  Knee pain associated with osteoarthritis, which required NSAID or other therapy for ≥&#xD;
             15 days during the preceding month&#xD;
&#xD;
          -  Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a&#xD;
             rating of Grade 2 or 3 in the target knee (does not include borderline Grade 2), as&#xD;
             confirmed by the Sponsor's designated rheumatologist through radiographic review of&#xD;
             x-ray(s) taken no more than 1 year prior to the Screening visit. (Sharpening of the&#xD;
             tibial spine is not considered to be an osteophyte) (See Appendix 4 for additional&#xD;
             details)&#xD;
&#xD;
          -  Meets pain assessment entry criteria as defined by Sponsor's pain eligibility&#xD;
             algorithm and calculated by the study Interactive Web Response System&#xD;
&#xD;
          -  No clinically significant change in physical activity and/or therapy for the past 3&#xD;
             months&#xD;
&#xD;
          -  Able to provide written informed consent prior to initiation of any clinical&#xD;
             trial-related procedures; and willing and able, in the opinion of the Investigator, to&#xD;
             comply with all requirements of the clinical trial for the duration of the trial (such&#xD;
             requirements include, but are not limited to: attending all study visits, refraining&#xD;
             from elective surgery or extensive travel during participation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Women of childbearing potential, or men whose sexual partner(s) is a woman of&#xD;
             childbearing potential may not be entered into the study if:&#xD;
&#xD;
               1. They are or intend to become pregnant (including use of fertility drugs) during&#xD;
                  the study&#xD;
&#xD;
               2. They are nursing&#xD;
&#xD;
               3. They are not using an acceptable, highly effective method of contraception until&#xD;
                  all follow-up procedures are complete. (Acceptable, highly effective forms of&#xD;
                  contraception are defined as: oral contraception, intrauterine device, systemic&#xD;
                  [injectable or patch] contraception, double barrier methods, naturally or&#xD;
                  surgically sterile, strict abstinence or partner has been sterilized. If&#xD;
                  hormonal-based birth control is being used, subject or subject's sexual&#xD;
                  partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit&#xD;
                  and maintained at the same dosing level throughout the 9-week clinical trial.)&#xD;
&#xD;
          -  Body Mass Index (BMI) over 40&#xD;
&#xD;
          -  A history of osteoarthritis symptoms that are completely non-responsive to&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator&#xD;
&#xD;
          -  Planned change (increase or decrease) in subject's level of physical activity (e.g.,&#xD;
             aerobic or anaerobic exercise) during the 6-week Treatment Period following&#xD;
             randomization&#xD;
&#xD;
          -  Enrollment in any trial and/or use of any Investigational Drug or device within the&#xD;
             immediate 30-day period prior to the Baseline visit&#xD;
&#xD;
          -  Enrollment in any study previously sponsored by Olatec Industries LLC, specifically&#xD;
             Study OLT1177-01 or OLT1177-02&#xD;
&#xD;
        Pain Related&#xD;
&#xD;
          -  Does not meet pain assessment entry criteria as defined by Sponsor's pain eligibility&#xD;
             algorithm and calculated by the study Interactive Web Response System&#xD;
&#xD;
          -  Clinically significant joint (other than the knee) or general pain at Baseline, at the&#xD;
             discretion of the Investigator&#xD;
&#xD;
        Musculoskeletal Related&#xD;
&#xD;
          -  Clinically significant, excessive effusion heat and/or redness in the target knee as&#xD;
             determined by the Investigator&#xD;
&#xD;
          -  Knock-kneed or bow-legged, as defined by a valgus or varus deformity of ≥ 15 degrees&#xD;
&#xD;
          -  Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a&#xD;
             rating of Grade 0, 1 or 4 in the target knee, as confirmed by the Sponsor's designated&#xD;
             rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior&#xD;
             to the Screening visit (sharpening of the tibial spine is not considered to be an&#xD;
             osteophyte)&#xD;
&#xD;
          -  Documented history of clinically significant pain associated with osteoarthritis of&#xD;
             the spine or hips, at the discretion of the Investigator&#xD;
&#xD;
          -  Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or&#xD;
             chondromalacia&#xD;
&#xD;
          -  Clinically significant medio-lateral and/or anterior-posterior instability, at the&#xD;
             discretion of the Investigator&#xD;
&#xD;
          -  Open surgery of the target knee within the prior year or surgery to the contralateral&#xD;
             knee or other weight-bearing joint within the prior year, if at the discretion of the&#xD;
             Investigator it would interfere with the study. If subject had open surgery more than&#xD;
             one-year prior, Sponsor's designated rheumatologist must confirm that such surgery did&#xD;
             not have any negative impact or consequence to the target knee (e.g., deformity of&#xD;
             angle to the bone, bone on bone, locking joints, etc.)&#xD;
&#xD;
          -  Arthroscopic surgery of the target knee within the prior six months&#xD;
&#xD;
          -  Any acute or chronic injury, other than osteoarthritis in the target knee, that will&#xD;
             be treated during the trial with any medication not allowed during the Treatment&#xD;
             Period&#xD;
&#xD;
          -  Prior surgery of the target knee requiring insertion of a medical device or surgical&#xD;
             hardware (e.g., screws)&#xD;
&#xD;
          -  Any major trauma or injury (including sports injuries) to the target knee in the past&#xD;
             12 months&#xD;
&#xD;
          -  Documented history of inflammatory joint disease, including but not limited to:&#xD;
             rheumatoid arthritis, gout, pseudogout, Paget's disease, psoriatic arthritis,&#xD;
             ankylosing spondylitis, chronic inflammatory disease (e.g., colitis), fibromyalgia&#xD;
             (diagnosed in accordance with ACR criteria, as applicable), articular fracture,&#xD;
             ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary&#xD;
             osteochondromatosis, heritable disorders (e.g., hypermobility) or collagen gene&#xD;
             mutations&#xD;
&#xD;
          -  Any planned interventional and/or surgical procedure during the 6-week Treatment&#xD;
             Period following randomization&#xD;
&#xD;
        Concomitant Conditions, Diseases, Medications/Therapies and Medical History Related&#xD;
&#xD;
          -  Any use of Rescue Medication within 24 hours prior to the Baseline visit or use of any&#xD;
             other pain medication within 7 days prior to Baseline visit&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as blood pressure ≥ 150/95 mmHg&#xD;
&#xD;
          -  A history of uncontrolled and untreated diabetes mellitus with an HbA1c level &gt; 8; or&#xD;
             blood sugar levels that are outside of the normal range and HbA1c level &gt; 8 is&#xD;
             subsequently confirmed&#xD;
&#xD;
          -  Any inflammatory skin condition over the target knee application area&#xD;
&#xD;
          -  Use of any prohibited concomitant medications/therapies during the 7-day Washout&#xD;
             Period or planned use of any prohibited concomitant medications/therapies during the 6&#xD;
             week Treatment Period&#xD;
&#xD;
          -  Use of intraarticular or intramuscular steroids in the target knee within the previous&#xD;
             3 months or in any other joint within the previous 30 days&#xD;
&#xD;
          -  Use of intraarticular hyaluronate in the target knee within the previous 6 months or&#xD;
             in any other joint within the previous 30 days&#xD;
&#xD;
          -  Current substance abuse or history of chronic substance abuse within the past year, or&#xD;
             prior chronic substance abuse (including alcoholism and/or addiction to pain&#xD;
             medications) that is determined at the discretion of the Investigator as likely to&#xD;
             interfere with trial assessments or recur during the trial&#xD;
&#xD;
          -  Use of any systemic (oral or parenteral) corticosteroids within the prior month&#xD;
&#xD;
          -  Uncontrolled psychiatric conditions (e.g., mania, depression, anxiety, substance&#xD;
             dependence of any kind) that would impair the subject from safely participating in the&#xD;
             trial, including completing any protocol requirements&#xD;
&#xD;
          -  Evidence of cognitive impairment including dementia that may interfere with subject's&#xD;
             ability to complete daily pain diaries requiring recall of average pain level in the&#xD;
             past 24 hours&#xD;
&#xD;
          -  Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal,&#xD;
             hematological or neurological disease or prior surgery that may interfere with the&#xD;
             subject successfully completing the trial, including completing any protocol&#xD;
             requirements as determined by the Investigator&#xD;
&#xD;
          -  History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or&#xD;
             antibodies to Hepatitis C Virus (HCV)&#xD;
&#xD;
          -  Diagnosed with any form of cancer within the past 5 years, except for treated basal&#xD;
             cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Any other medical conditions, diseases or prior surgeries that in the opinion of the&#xD;
             Investigator would impair the subject from safely participating in the trial and/or&#xD;
             completing any protocol requirements&#xD;
&#xD;
          -  Active infection within 3 days of the Baseline visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Cunningham, MD, FAAD</last_name>
    <role>Study Chair</role>
    <affiliation>Cu-Tech, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consulting, LLC</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research, Inc.</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - US, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates, LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trial, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network, Inc.</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center, LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <disposition_first_submitted>April 3, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 6, 2017</disposition_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapansutrile</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

